Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study
- PMID: 20486907
- PMCID: PMC2891375
- DOI: 10.1111/j.1600-6143.2010.03126.x
Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study
Abstract
Although mortality rates following liver transplantation (LT) are well described, there is a lack of detailed, prospective studies determining patterns of and risk factors for long-term mortality. We analyzed the multicenter, prospectively obtained The National Institute of Diabetes and Digestive and Kidney Diseases LT Database of 798 transplant recipients from 1990 to 1994 (follow-up 2003). Overall, 327 recipients died. Causes of death >1 year: 28% hepatic, 22% malignancy, 11% cardiovascular, 9% infection, 6% renal failure. Renal-related death increased dramatically over time. Risk factors for death >1 year (univariate): male gender, age/decade, pre-LT diabetes, post-LT diabetes, post-LT hypertension, post-LT renal insufficiency, retransplantation >1 year, pre-LT malignancy, alcoholic disease (ALD) and metabolic liver disease, with similar risks noted for death >5 years. Hepatitis C, retransplantation, post-LT diabetes, hypertension and renal insufficiency were significant risk factors for liver-related death. Cardiac deaths associated with age, male gender, ALD, cryptogenic disease, pre-LT hypertension and post-LT renal insufficiency. In summary, the leading causes of late deaths after transplant were graft failure, malignancy, cardiovascular disease and renal failure. Older age, diabetes and renal insufficiency identified patients at highest risk of poor survival overall. Diligent management of modifiable post-LT factors including diabetes, hypertension and renal insufficiency may impact long-term mortality.
Conflict of interest statement
No conflicts of interest for any of the authors
Figures



Similar articles
-
Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.Dig Liver Dis. 2009 May;41(5):350-6. doi: 10.1016/j.dld.2008.09.018. Epub 2008 Nov 28. Dig Liver Dis. 2009. PMID: 19046932
-
Analysis of adult 20-year survivors after liver transplantation.Hepatol Int. 2015 Jul;9(3):461-70. doi: 10.1007/s12072-014-9577-x. Epub 2014 Sep 18. Hepatol Int. 2015. PMID: 25788182 Free PMC article.
-
Liver transplantation: role of immunosuppression, renal dysfunction and cardiovascular risk factors.Minerva Chir. 2012 Feb;67(1):1-13. Minerva Chir. 2012. PMID: 22361672
-
Metabolic syndrome and liver transplantation: a review and guide to management.J Hepatol. 2010 Jul;53(1):199-206. doi: 10.1016/j.jhep.2010.01.040. Epub 2010 Mar 31. J Hepatol. 2010. PMID: 20451282 Review.
-
Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review.Expert Rev Gastroenterol Hepatol. 2013 May;7(4):361-4. doi: 10.1586/egh.13.19. Expert Rev Gastroenterol Hepatol. 2013. PMID: 23639094 Review.
Cited by
-
Liver transplantation with simultaneous splenectomy increases risk of cancer development and mortality in hepatocellular carcinoma patients.World J Gastrointest Surg. 2022 Sep 27;14(9):930-939. doi: 10.4240/wjgs.v14.i9.930. World J Gastrointest Surg. 2022. PMID: 36185566 Free PMC article.
-
Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients.Hepatobiliary Surg Nutr. 2022 Jun;11(3):400-411. doi: 10.21037/hbsn-20-568. Hepatobiliary Surg Nutr. 2022. PMID: 35693397 Free PMC article. Review.
-
Cardiovascular Evaluation of Liver Transplant Patients by Using Coronary Calcium Scoring in ECG-Synchronized Computed Tomographic Scans.J Clin Med. 2021 Nov 2;10(21):5148. doi: 10.3390/jcm10215148. J Clin Med. 2021. PMID: 34768667 Free PMC article.
-
De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation.World J Hepatol. 2021 Dec 27;13(12):1991-2004. doi: 10.4254/wjh.v13.i12.1991. World J Hepatol. 2021. PMID: 35070003 Free PMC article. Review.
-
Spotlight on Impactful Research: Utilization of Aspirin and Statin in Management of Coronary Artery Disease in Patients With Cirrhosis Undergoing Liver Transplant Evaluation.Clin Liver Dis (Hoboken). 2020 Mar 26;15(2):69-70. doi: 10.1002/cld.899. eCollection 2020 Feb. Clin Liver Dis (Hoboken). 2020. PMID: 32226618 Free PMC article. Review.
References
-
- Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, AJ O. Late mortality after orthotopic liver transplantation. Am J Surg. 2001;181(5):475–479. - PubMed
-
- Jain A, Marcos A, Reyes J, Mazariagos G, Kashyap R, Eghtesad B, et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. Transplant Proc. 2005;37(2):1207–1210. - PubMed
-
- Pruthi J, Medkiff K, Esrason K, Donovan J, Yoshida E, Erb S, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001;7:811–815. - PubMed
-
- Pfitzmann R, Nüssler N, Hippler-Benscheidt M, Neuhaus R, Neuhaus P. Long-term results after liver transplantation. Transpl Int. 2008;21(3):234–246. - PubMed
-
- Lukes D, Herlenius G, Rizell M, Mjörnstedt L, Bäcman L, M MO, et al. Late mortality in 679 consecutive liver transplant recipients: the Gothenburg liver transplant experience. Transplant Proc. 2006;38:2671–2672. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical